The Israeli cannabis supplier has received EU-GMP certification from the German Federal Ministry of Health for the production, export, and marketing of medical cannabis in Europe
Cannbit-Tikun Olam Israel was founded in 2006 and was acquired Cannbit Pharmaceuticals in 2019 production facility in the north of Israel and cultivation farm near the Dead Sea have both received the certification which will allow for the commercial export of medical cannabis to Europe.
The company said this will make it possible to implement an existing agreement with German pharmaceutical company, Fette Pharma, that will have its products exported to Germany, Austria and Switzerland.
Cannbit-Tikun Olam Israel is joining the highly select group of international medical cannabis companies with EU-GMP certification which is required for the production, export and marketing of pharmaceuticals throughout Europe.
Avinoam Sapir, CEO of Cannbit-Tikun Olam commented: “Receiving the prestigious European certification is the company’s most important strategic move to date and is a true breakthrough for our company and the entire Israeli cannabis industry. Now having the certificate, we can provide an alternative for some chemical drugs, which is a clinically proven solution to improve patients’ quality of life worldwide.
“From now on, our clinical research-based indication-specific products and in the future unique and innovative administration forms will be sold in European pharmacies, I invite pharmaceutical companies to join us to plant the seeds of the future.”
Tikun Olam Israel was founded in 2006 and acquired Cannbit Pharmaceuticals in 2019. As Israel’s first and leading cannabis supplier, the company has treated tens of thousands of patients across the country.
With 15 years of clinical research experience and over 35 clinical and preclinical studies under its belt, the company said it aims to “ensure an ecosystem that combines the values of sustainability, continuity of care and standardisation of the quality of its products”.
Cannbit-Tikun Olam Israel said it will now act to sign additional global production agreements to produce its medical cannabis products in commercial quantities worldwide.
